EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Effectiveness of Secukinumab in Congenital Ichthyoses: A Retrospective Monocentric Case Series

Orsola Crespi iD, Umberto Santaniello iD, Luca Cangialosi, Ambra Bonvicino, Michela Ortoncelli, Francois Rosset iD, Luca Mastorino iD, Simone Ribero iD, Pietro Quaglino

Antibodies · 11.08.2026 · 15 (4) · 74

DOI: 10.3390/antib15040074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibodies, online erschienen am 11.08.2026. Verfasst von Orsola Crespi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dermatologic Clinic, Department of Medical Science, University of Turin, 10126 Turin, Italy. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Congenital ichthyoses (CI) are inherited disorders of keratinization characterized by epidermal barrier dysfunction, abnormal desquamation, and variable degrees of inflammation. Increasing evidence suggests a role for IL-23/Th17-mediated immune dysregulation in some CI subtypes, providing a rationale for targeted biologic therapies. Secukinumab, an anti-IL-17A monoclonal antibody, has emerged as a potential therapeutic option, although real-world evidence remains limited. This study evaluated the effectiveness of secukinumab in adult patients with severe CI.

Methods

We performed a retrospective monocentric case series including eight adult patients with severe congenital ichthyosis treated with secukinumab for at least six months and followed for up to 56 months. Clinical outcomes included Investigator Global Assessment (IGA) scores for erythema, scaling, scalp involvement, and palmoplantar hyperkeratosis, together with pruritus assessed by Numeric Rating Scale (NRS).

Results

Erythema and scaling showed most of their improvement during the first six months of treatment, after which mean clinical scores remained relatively stable throughout follow-up. At the last available assessment, improvement rates were 100% for erythema, 87.5% for trunk and limb scaling, 100% for scalp scaling, and 75% for palmoplantar hyperkeratosis. Hyperkeratosis showed a less pronounced response than inflammatory manifestations. Pruritus improved within the first 3–4 months of treatment and was sustained over time, with mean NRS scores decreasing from 6.5 at baseline to below 4 within 3–4 months. No discontinuations due to adverse events or lack of efficacy were recorded.

Conclusions

Secukinumab was associated with clinically meaningful improvements in inflammatory manifestations of CI, particularly erythema and pruritus, while showing a more limited effect on hyperkeratotic features. These findings support the potential role of IL-17 inhibition in selected CI phenotypes.

Schlagwörter

Stichwörter der Autor:innen

IL-17 inhibitioncongenital ichthyosislamellar ichthyosisreal-world evidencesecukinumab

Autor:innen und Institutionen

  • Dermatologic Clinic, Department of Medical Science, University of Turin, 10126 Turin, Italy.
  • Department of Dermatology, Beauregard Hospital, Azienda USL della Valle d'Aosta, Via L. Vaccari 5, 11100 Aosta, Italy.

ORCID-Profile: Orsola Crespi, Umberto Santaniello, Francois Rosset, Luca Mastorino, Simone Ribero

Zitieren

APA

Crespi, O., Santaniello, U., Cangialosi, L., Bonvicino, A., Ortoncelli, M., Rosset, F., Mastorino, L., Ribero, S., & Quaglino, P. (2026). Real-World Effectiveness of Secukinumab in Congenital Ichthyoses: A Retrospective Monocentric Case Series. Antibodies, 15(4), 74. https://doi.org/10.3390/antib15040074

Vancouver

Crespi O, Santaniello U, Cangialosi L, Bonvicino A, Ortoncelli M, Rosset F, et al. Real-World Effectiveness of Secukinumab in Congenital Ichthyoses: A Retrospective Monocentric Case Series. Antibodies. 2026;15(4):74. doi:10.3390/antib15040074

BibTeX
@article{Crespi2026,
  author = {Crespi, Orsola and Santaniello, Umberto and Cangialosi, Luca and Bonvicino, Ambra and Ortoncelli, Michela and Rosset, Francois and Mastorino, Luca and Ribero, Simone and Quaglino, Pietro},
  title = {Real-World Effectiveness of Secukinumab in Congenital Ichthyoses: A Retrospective Monocentric Case Series},
  journal = {Antibodies},
  year = {2026},
  volume = {15},
  number = {4},
  pages = {74},
  doi = {10.3390/antib15040074}
}
Kostenlos starten →